Manufacturing of Cell & Gene Therapies & Vaccines
Ireland has a strong reputation as a Centre of Excellence for biopharmaceutical production. All of the top 10 global pharmaceutical companies have a presence in Ireland and the sector as a whole employs over 30,000 people and contributes €54 billion in exports. There has been significant, sustained investment in recent years and this is set to continue due to the benefits which companies see in our highly skilled workforce, proven track record and the supportive ecosystem.
Vaccines and cell and gene therapies (CGTs) are an emerging and rapidly growing area of interest and Ireland is poised to continue expansion of manufacturing into this exciting area. This programme will provide students with an appreciation of the science and challenges associated with CGT and vaccine manufacture as part of their continuing professional development (CPD) and support them to pursue a successful career in the field.
The programme and its academic faculty are closely linked with the National Institute for Bioprocess Research and Training (NIBRT) which is a global centre of excellence for training and research in biomanufacturing. Content will be delivered by a blend of industrial leaders and academic experts using a hybrid approach ensuring a high quality, relevant curriculum accessible both in person and remotely.
Vision and Values Statement
The Professional Certificate in Manufacturing of Cell and Gene Therapies and Vaccines provides training in the requisite knowledge for professional engineers and scientists seeking to work in the manufacture of cell and gene therapies and vaccines or related sectors. The programme covers the scientific, technical and regulatory issues associated with this emerging and rapidly growing field.
The programmes teaching methods are varied including lectures, case studies and facility tours. Material is delivered by a range of academic leaders and industry experts active in this field in a hybrid manner to allow both face to face and remote study. Student assessment is primarily achieved through continuous assessment.
It is anticipated that graduates of this programme will play an important role in the development, design and operation of processes capable of manufacturing cell and gene therapies and vaccines, the number of which will increase rapidly in the coming years.
MEngSc Biopharmaceutical Engineering PT
MEngSc Biopharmaceutical Engineering FT
MEngSc Chemical Engineering FT
The modules will be delivered in a hybrid format with the option to attend in-person lectures on the UCD campus or to study remotely. Lectures will take place on Friday evenings from 2 - 6 pm over the Spring trimester (12 weeks, Jan - May).
Cell Therapy Technologies and Processing
Gene Therapy and Vaccine Technologies and Processing
GMP Manufacturing of Advanced Therapeutics
How to apply?
The following entry routes are available:
PC Manufacturing of Cell & Gene Therapies & Vaccines JanPT (T372)
* Courses will remain open until such time as all places have been filled, therefore early application is advised
The first intake for this course will be January 2024. Applications will open January 2023.
6 months Part-Time.
The modules will be delivered in a hybrid format with the option to attend in-person lectures on the UCD campus or to study remotely. Lectures will take place on Friday evenings from 2pm - 6pm over the Spring trimester (12 weeks, January - May).
Post Course Info
Career & Graduate Study Opportunity
The Professional Certificate is suitable for Science and Engineering graduates currently working in the biopharmaceutical industry or looking to move into the sector, who wish to expand their skill set to take advantage of the growth in the vaccine, and cell and gene therapies space. The number of companies active in this area is currently growing with Pfizer, Takeda, WuXi, MeiraGTx, VLE, Avectas, Onk and Orbsen Therapeutics leading the way.
The credits gained can be used toward further postgraduate qualifications offered by UCD should participants wish to pursue a higher qualification e.g. Graduate Certificate (30 credits) / Graduate Diploma (60 credits)/ MEngSc in Biopharmaceutical Engineering (90 credits).